Evicenter
Vabysmo (faricimab-svoa) in Neovascular age-related macular degeneration
Manufacturer
Genentech, Inc.
Prescribing information
Vabysmo (opens in a new tab)
Questions
12
Last updated

All questions

Clinical trials: Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration

5 questions · 5 sources

Clinical trials

How were the Vabysmo wet AMD trials (TENAYA and LUCERNE) designed?

Note: The second Prescribing Information passage continues the sentence that ends the first, across a page break of the label.

Study results

How well does Vabysmo work vs aflibercept for wet AMD (TENAYA, LUCERNE)?

Note: Table 2 columns are VABYSMO and aflibercept in TENAYA, then VABYSMO and aflibercept in LUCERNE, in that order.

How many wet AMD patients were on Vabysmo every 16 weeks at week 48?

Does Vabysmo reduce retinal thickness (CST) in wet AMD trials?

Note: The drying page of the VABYSMO HCP site presents the nAMD central subfield thickness (CST) results as a graph; the quoted text is the assessment and limitations statement printed with it.

Subgroup results

Were Vabysmo wet AMD results consistent across age, sex, race, and baseline vision?